No Data
No Data
No Data
No Data
No Data
Assessing BioNTech: Insights From 11 Financial Analysts
Ratings for BioNTech (NASDAQ:BNTX) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
BenzingaApr 17 22:00
HC Wainwright & Co. : The BioNTech (BNTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $107.00.
HC Wainwright & Co. : The BioNTech (BNTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $107.00.
Zhitong FinanceApr 17 18:30
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $107 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $107 price target.
BenzingaApr 17 18:24
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB) and Clene (CLNN) with bullish sentiments.
TipRanksApr 17 18:20
TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio, BioNTech, BiOneCure Therapeutics
New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio,
GlobeNewswireApr 10 01:00
BioNTech SE Virtual AGM Scheduled for May 2024
TipRanksApr 9 05:27
No Data
No Data